Arvinas To Report Second Quarter 2025 Financial Results On August 6, 2025

(MENAFN- GlobeNewsWire - Nasdaq) NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.

The webcast can be accessed under“Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at following the completion of the event.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
...

Media:
Kirsten Owens
+1 (203) 584-0307
...

MENAFN30072025004107003653ID1109864813